Can't paste a link but today's 8-K includes interesting verbiage and display's the slides that were presented yesterday. (I would expect the slides to be available at the company web site soon.) The 8-K indicates that these slides will be used in "several upcoming investor presentations."
The stabilization in ambulatory ALS patients, as indicated by the graphs, is striking. From yesterdays presentation, more data points confirming these charts should be forthcoming.
The presentation slides from 1-8 are now available on the Neuralstem website under the "Investor" tab. The info on pages 9-11 is very thought provoking. It appears that the more stem cells they inject and the more places they inject them the better the patient does. Hopefully when the ALS trial ends in Feb we'll get some more data points.